Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2019 /
PARP inhibitors for metastatic breast cancer

27th Sep - 1st Oct 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.10.19
Views: 3745

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

Prof Michael Untch speaks to ecancer at ESMO 2019 in Barcelona about some of the trials covering PARP inhibitors for metastatic breast cancer.

Prof Untch outlines the OlympiAD and EMBRACA trials for patients with BRCA mutations, both with positive results.

He also touches on the BrighTNess study which involves a new PARP inhibitor, veliparib.

This programme has been supported by an unrestricted educational grant from Pfizer.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation